Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
The Novartis CEO believes the west has much to learn, especially in terms of clinical trial regulations and enrolment.
The co-principal investigator of OCEANIC-STROKE tells Scrip that the oral Factor XIa inhibitor could be paradigm-changing.
The blood cancer drug and the cholesterol lowerer will be major growth drivers through to 2020 and beyond.
Sales set to rise at low single digits this year but profits will be down slightly as generics take a grip on big earners like Entresto.
The CHMP has delivered a negative trend vote on the US firm's filing for Daybue.
The Danish drugmaker is getting ready to celebrate a first-in-class approval from the European Commission for semaglutide for metabolic dysfunction-associated steatohepatitis.